Agreements (Details 3) (Sanofi, USD $)	1 Months Ended			21 Months Ended							1 Months Ended		132 Months Ended				12 Months Ended		12 Months Ended			1 Months Ended
	Aug. 31, 2011 Right-to-test agreement	Aug. 31, 2008 Right-to-test agreement	Dec. 31, 2006 Right-to-test agreement	Aug. 31, 2008 Right-to-test agreement	Jun. 30, 2014 Development and Commercialization License	Dec. 31, 2006 Development and Commercialization License	Dec. 31, 2006 Development and Commercialization License Maximum	Jun. 30, 2014 Development and Commercialization License Phase I clinical trial	Dec. 31, 2006 Development and Commercialization License Development milestones	Dec. 31, 2006 Development and Commercialization License Regulatory milestones	Dec. 31, 2013 Development and Commercialization License Exclusive license	Jul. 31, 2003 Development and Commercialization License Exclusive license item	Jun. 30, 2014 Development and Commercialization License Exclusive license	Jul. 31, 2003 Development and Commercialization License Exclusive license Maximum	Jul. 31, 2003 Development and Commercialization License Exclusive license Development milestones	Jul. 31, 2003 Development and Commercialization License Exclusive license Regulatory milestones	Jun. 30, 2013 Development and Commercialization License Exclusive license Undisclosed Target	Jun. 30, 2014 Development and Commercialization License Exclusive license Undisclosed Target Phase I clinical trial	Jun. 30, 2012 Development and Commercialization License Exclusive license SAR3419 Phase IIb clinical trial	Jun. 30, 2014 Development and Commercialization License Exclusive license SAR3419 Development milestones Phase III clinical trial	Jun. 30, 2014 Development and Commercialization License Exclusive license SAR566658 Development milestones Phase IIb clinical trial	Jul. 31, 2014 Development and Commercialization License Exclusive license SAR650984 Phase IIb clinical trial Subsequent event	Jun. 30, 2014 Development and Commercialization License Exclusive license SAR650984 Development milestones Phase III clinical trial	Jun. 30, 2014 Development and Commercialization License Exclusive license SAR408701 Phase I clinical trial
Collaborative Agreements disclosures
Number of undisclosed compounds with exclusive licenses												1
Potential milestone payments receivable					$ 2,000,000		$ 30,000,000	$ 2,000,000	$ 10,000,000	$ 20,000,000				$ 21,500,000	$ 7,500,000	$ 14,000,000		$ 1,000,000		$ 3,000,000	$ 3,000,000		$ 3,000,000	$ 1,000,000
Payments received under collaboration agreement		3,500,000	500,000	4,000,000									16,500,000				500,000		3,000,000			3,000,000
License exercise fee, per license						2,000,000
Fee received per license											2,000,000
Term of agreement	3 years		3 years
Payments for extension of agreement	$ 2,000,000